Search Within

Jedd D Wolchok

  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (35)
  2. Meeting Abstract (23)
  3. Editorial (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (60)
  2. GSK Faculty (60)
  3. Gastrointestinal Oncology Service (60)
  4. Melanoma and Immunotherapeutics Service (60)
  5. Solid Tumor Oncology Division (60)
  6. Hematologic Malignancies, Division of (30)

More Groups

People
  1. Michael Postow (23)
  2. Neil Segal (23)
  3. James Harding (17)
  4. Margaret Callahan (15)
  5. Paul Chapman (13)
  6. Taha Merghoub (11)

More People

Years
  1. 2022 (3)
  2. 2021 (2)
  3. 2020 (1)
  4. 2019 (3)
  5. 2018 (7)
  6. 2017 (4)

More Years

Publications
  1. Journal of Clinical Oncology (17)
  2. Journal for ImmunoTherapy of Cancer (5)
  3. Cancer Immunity (4)
  4. Clinical Cancer Research (3)
  5. European Journal of Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (17)
  2. American Association for Cancer Research (7)
  3. Biomed Central Ltd (5)
  4. Academy of Cancer Immunology (4)
  5. Elsevier Inc. (4)
  6. Nature Publishing Group (3)

More Publishers

Results (60)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to control tumors systemically
    Meeting Abstract

    Khalil, D. N.; Campesato, L. F.; Li, Y.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
    Meeting Abstract

    Segal, N. H.; Infante, J. R.; Sanborn, R. E.; Gibney, G. T.; Lawrence, D. P.; Rizvi, N.; Leidner, R.; Gajewski, T. F.; Bertino, E.; Sharfman, W. H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • An open-label, dose-escalation phase I study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma
    Journal Article

    Khalil, D. N.; Postow, M. A.; Ibrahim, N.; Ludwig, D. L.; Cosaert, J.; Kambhampati, S. R. P.; Tang, S.; Grebennik, D.; Kauh, J. S. W.; Lenz, H. J.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
    Journal Article

    Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.; Cunningham, J.; Page, D. B.; Postow, M. A.; Weinstein, A.; Lucas, A. S.; Ciccolini, K. T.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy
    Journal Article

    Khalil, D. N.; Smith, E. L.; Brentjens, R. J.; Wolchok, J. D.
    Nature Reviews Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Journal Article

    Belum, V. R.; Benhuri, B.; Postow, M. A.; Hellmann, M. D.; Lesokhin, A. M.; Segal, N. H.; Motzer, R. J.; Wu, S.; Busam, K. J.; Wolchok, J. D.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
    Meeting Abstract

    Khalil, D.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2015)

    Fulltext@MSK | Save
  • The new era of cancer immunotherapy: Manipulating T-cell activity to overcome malignancy
    Journal Article

    Khalil, D. N.; Budhu, S.; Gasmi, B.; Zappasodi, R.; Hirschhorn-Cymerman, D.; Plitt, T.; De Henau, O.; Zamarin, D.; Holmgaard, R. B.; Murphy, J. T.; more...
    Advances in Cancer Research (2015)

    Fulltext@MSK | Save
  • Pneumonitis with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Naidoo, J.; Cunningham, J.; Woo, K. M.; Hellmann, M. D.; Postow, M. A.; Drilon, A. E.; Chaft, J. E.; Lesokhin, A. M.; Segal, N. H.; Callahan, M. K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save